Houston、TXにおける膠芽腫の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、膠芽腫に関する26件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
被験者募集中第3相
- University of Texas Houston Health Science Center, Houston
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
被験者募集中第2/3相
- University of Texas - MD Anderson Cancer Center, Houston
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
被験者募集中第1相
- Baylor St. Luke's Medical Center, Houston
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
被験者募集中第1相
- MD Anderson Cancer Center, Houston
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
被験者募集中第1相
- M D Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
被験者募集中第1/2相
- Baylor College of Medicine, Houston
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
Anti-GD2 ADC M3554 in Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
Targeted Pediatric High-Grade Glioma Therapy
被験者募集中観察研究
- Texas Children's Hospital, Houston
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Study of Olutasidenib and Temozolomide in HGG
被験者募集中第2相
- Texas Children's Hospital, Houston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
被験者募集中第3相
- MD Anderson Cancer Center, Houston
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
被験者募集中第1相
- Excel Diagnostics & Nuclear Oncology Center, Houston
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
被験者募集中第1/2相
- The University of Texas M. D. Anderson Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
被験者募集中健康なボランティア歓迎
- M D Anderson Cancer Center, Houston
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
被験者募集中第2相
- M D Anderson Cancer Center, Houston
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
被験者募集中第2相
- UTHealth Houston, Houston
- Baylor College of Medicine, Houston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
被験者募集中早期第1相健康なボランティア歓迎
- Texas Children's Hospital, Houston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
被験者募集中第2相
- Texas Children's Hospital, Houston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
被験者募集中第1/2相
- Houston Methodist Neurological Institute, Houston
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
被験者募集中第1/2相
- Houston Methodist Neurological Institute, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
被験者募集中第1相
- UT MD Anderson Cancer Center, Houston
他の都市における膠芽腫の試験
- New York City, NY30件の研究
- Boston, MA28件の研究
- Los Angeles, CA24件の研究
- Durham, NC20件の研究
- San Francisco, CA17件の研究
- Chicago, IL15件の研究
- Washington, DC15件の研究
- Columbus, OH14件の研究
- Miami, FL14件の研究
- Rochester, MN13件の研究
- Jacksonville, FL13件の研究
- Aurora, CO12件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。